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Whole-genome sequencing identifies non-coding variants 1 
near EN1 with large effects on bone mineral density  2 
SUPPLEMENTARY INFORMATION 3 
1. Cohorts 4 
Cohort-level characteristics are described in Supplementary Table 18. Supplementary Table 19 5 
describes BMD measurements and covariates used in association testing for all cohorts. 6 
2. Sequencing 7 
Supplementary Table 20 summarizes the data generation method for sequencing-based cohorts. A 8 
detailed description is provided below for the whole genome and whole exome sequenced cohorts. 9 
Whole Genome Sequencing 10 
UK10K 11 
ALSPAC and TwinsUK cohorts were sequenced to an average read depth of 6.7x through the UK10K 12 
program (www.uk10k.org). Whole genome sequencing was completed at the Wellcome Trust Sanger 13 
Institute and Beijing Genomics Institute. Briefly, DNA was sheared and subjected to Illumina paired-end 14 
DNA library preparation and sequenced using the Illumina HiSeq platform. Reads were aligned to the 15 
GRCh37 human reference, using BWA (v0.5.9-r16).1 BAM files were further processed to realign around 16 
known INDELs, base quality score recalibration, addition of BAQ tags using GATK.  17 
 18 
SNV calls were completed using samtools/bcftools (version 0.1.18-r579),2 and were then called to produce 19 
a VCF file.3 The pipeline to create these calls is available from: 20 
https://github.com/VertebrateResequencing/vr-codebase/tree/develop. 21 
 22 
Sites were called using the Variant Quality Score Recalibration (VQSR)4 and GATK Unified Genotyper 23 
was used to recall the sites and alleles discovered by samtools. The VariantRecalibrator within GATK was 24 
used to first model the variants, then GATK ApplyRecalibration was applied to assign VQSLOD scores 25 
(see http://www.broadinstitute.org/gsa/wiki/index.php/Variant_quality_score_recalibration for more 26 
details). 27 
 28 
VQSLOD score threshold was set at -0.6804 which improved site concordance with duplicate samples 29 
sequenced using high-depth exome sequence methods. Two further thresholds were applied: failure of 30 
HWE (P<1e-6) and evidence of batch effects between samples genotyped at Sanger and BGI (P<1e-2). In 31 
total, 4.2M variants were removed through these QC criteria. The final set contained over 42M SNVs.  32 
 33 
In order to assess the validity of the sequence data, 61 samples were also sequenced using high-depth next 34 
generation exome sequencing (depth  = 70x), described previously.5 74,621 sites were shared out of the 35 
86,322 sites that were called in the exome data, representing a sensitivity of 86.4% across the 35Mb bait 36 
region. We assessed the non-reference discordance rate and found that 0.2% were discordant, suggesting 37 
that the resultant dataset had high concordance with high depth exome sequencing. 38 
Whole Exome Sequencing 39 
AOGC 40 
993 samples underwent exome capture and massive parallel sequencing.  Sequencing libraries were 41 
constructed from 1.6ug genomic DNA using the Illumina TruSeqDNA sample preparation kit. Libraries 42 
were combined in pools of six for target capture using the Illumina TruSeq Exome Enrichment Kit. 43 
Libraries were assessed pre- and post-capture for both quality and yield using the Agilent High Sensitivity 44 
DNA assay and KAPA Library Quantification Kit. Massively parallel sequencing was performed using the 45 
Illumina HiSeq2000 to generate 100bp paired-end reads (2x100PE). Either 6 or 12 samples were run per 46 
flow cell lane using version 2 or version 3 SBS reagents respectively.  47 
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Illumina Data Analysis Pipeline software (CASAVA 1.8.2) was used for de-multiplexing and initial base 48 
calling and sequence data was aligned to the current build of the human genome (hg19, released February 49 
2009) using the Novoalign alignment tool (V2.08.02); sequence alignment files were converted using 50 
SAMtools (v0.1.16) and Picard tools (http://picard.sourceforge.net)  (v1.42) SNPs and indels were called 51 
using the Genome Analysis Toolkit (GATK v2.2-3)6 including variant recalibration. Variants were 52 
annotated using ANNOVAR and Variant Effect Predictor and GERP++ scores.7,8 53 
FHS 54 
DNA samples were constructed into Illumina paired-end pre-capture libraries according to the 55 
manufacturer’s protocol (Illumina Multiplexing_SamplePrep_Guide_1005361_D) with modifications as 56 
described in the BCM-HGSC Illumina Barcoded Paired-End Capture Library Preparation protocol. 57 
Libraries were prepared using Beckman robotic workstations (Biomek NXp and FXp models).  The 58 




Briefly, 1 μg of DNA in 100ul volume was sheared into fragments of approximately 300-400 base pairs in 63 
a Covaris plate with E210 system (Covaris, Inc. Woburn, MA) followed by end-repair, A-tailing and 64 
ligation of the Illumina multiplexing PE adaptors.  Pre-capture Ligation Mediated-PCR (LM-PCR) was 65 
performed for 6-8 cycles of amplification using the 2X SOLiD Library High Fidelity Amplification Mix (a 66 
custom product manufactured by Invitrogen).  Universal primer IMUX-P1.0 and a pre-capture barcoded 67 
primer IBC were used in the PCR amplification.  In total, a set of 12 such barcoded primers were used on 68 
these samples.  Purification was performed with Agencourt AMPure XP beads after enzymatic reactions.  69 
Following the final XP beads purification, quantification and size distribution of the pre-capture LM-PCR 70 
product was determined using the LabChip GX electrophoresis system (PerkinElmer). 71 
 72 
For the hybridization step, four or six pre-capture libraries were pooled together (~250 ng/sample for a 4-73 
plex and ~166 ng/sample for a 6-plex, totaling 1 μg per pool).  These pooled libraries were then hybridized 74 
in solution to the HGSC VCRome 2.1 design (42Mb, NimbleGen) according to the manufacturer’s protocol 75 
NimbleGen SeqCap EZ Exome Library SR User’s Guide (Version 2.2) with minor revisions.  Human COT1 76 
DNA and full-length Illumina adaptor-specific blocking oligonucleotides were added into the hybridization 77 
to block repetitive genomic sequences and the adaptor sequences.  Post-capture LM-PCR amplification was 78 
performed using the 2X SOLiD Library High Fidelity Amplification Mix with 14 cycles of amplification.  79 
After the final AMPure XP bead purification, quantity and size of the capture library was analyzed using 80 
the Agilent Bioanalyzer 2100 DNA Chip 7500.  The efficiency of the capture was evaluated by performing 81 
a qPCR-based quality check on the four standard NimbleGen internal controls.  Successful enrichment of 82 
the capture libraries was estimated to range from a 6 to 9 of ΔCt value over the non-enriched samples. 83 
 84 
Library templates were prepared for sequencing using Illumina’s cBot cluster generation system with 85 
TruSeq PE Cluster Generation Kits.  Briefly, these libraries were denatured with sodium hydroxide and 86 
diluted to 6-9 pM in hybridization buffer in order to achieve a load density of ~800K clusters/mm2.  Each 87 
library pool was loaded in a single lane of a HiSeq flow cell, and each lane was spiked with 1% phiX 88 
control library for run quality control.  The sample libraries then underwent bridge amplification to form 89 
clonal clusters, followed by hybridization with the sequencing primer.  Sequencing runs were performed in 90 
paired-end mode using the Illumina HiSeq 2000 platform.  Using the TruSeq SBS Kits, sequencing-by-91 
synthesis reactions were extended for 101 cycles from each end, with an additional 7 cycles for the index 92 
read. 93 
RS-I 94 
Genomic DNA of RS participants were prepared from blood and fragmented into 200-400 bp fragments 95 
using Covaris Adaptive Focused Acoustics (AFA) shearing according to the manufacturer¹s instructions 96 
(Covaris, Inc., Woburn, MA). Illumina TruSeq DNA Library preparation (Illumina, Inc., San Diego, CA) 97 
was performed on a Caliper Sciclone NGS workstation (Caliper Life Sciences, Hopkinton, MA), followed 98 
by exome capture using the Nimblegen SeqCap EZ V2 kit (Roche Nimblegen, Inc., Madison, WI). This 99 
capture targets 44Mb of exonic regions covering 30,246 coding genes, 329,028 exons and 710 miRNAs. 100 
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Paired-end 2 x100 sequencing was performed on Illumina HiSeq2000 sequencer using Illumina TruSeq V3 101 
chemistry. 102 
 103 
Reads were mapped to the human genome hg19 with the BWA algorithm and processed with the Genome 104 
Analysis Toolkit (GATK) to recalibrate base quality-scores and perform local realignment around known 105 
indels.  106 
 107 
Variant calling and Quality Control 108 
Target coverage or each sample was computed with the GATK. Single nucleotide variants (SNVs) and 109 
small insertions and deletions (indels) were called with the Unified Genotyper module of the GATK and 110 
filtered to remove SNVs with annotations indicative of technical artifacts (such as strand-bias, low variant 111 
call quality, or homopolymer runs). Samples with fewer than 76% of targeted bases covered to 20x, with an 112 
abnormally high number of non-reference alleles or heterozygosity, or with an abnormally low 113 
concordance with prior SNP array genotypes (based on the distribution across all samples) were excluded 114 
from analysis. Any sample genotype at a site with a genotype quality (GQ) < 20 in the sample was ignored 115 
(e.g. set as missing). Variants were annotated with the Variant Effect Predictor.7 116 
ESP 117 
The processes of library construction, exome capture, sequencing, and mapping were performed as 118 
previously described. Sequencing was performed at the University of Washington (UW) and the Broad 119 
Institute of MIT/Harvard (Broad). Single Nucleotide Variants (SNVs) were called using the UMAKE 120 
pipeline at University of Michigan, which allowed all samples to be analyzed simultaneously, both for 121 
variant calling and filtering. Briefly, we used BAM files summarizing Burrows-Wheeler Alignment (BWA) 122 
alignments generated at the UW and the Broad as input.9 These BAM files summarized alignments 123 
generated by BWA, refined by duplicate removal, recalibration, and indel re-alignment. We excluded all 124 
reads that were not confidently mapped (Phred-scaled mapping quality < 20) from further analysis. To 125 
avoid PCR artifacts, we clipped overlapping ends in paired reads. We then computed genotype likelihoods 126 
for exome targeted regions and 50 flanking bases, accounting for per base alignment quality (BAQ) using 127 
SAMtools.9 Variable sites and their allele frequencies were identified using a maximum-likelihood model, 128 
implemented in glfMultiples.10 These analyses assumed a uniform prior probability of polymorphism at 129 
each site. The final call-set was performed on 6,823 samples. 130 
 131 
We used a support vector machine (SVM) classifier to separate likely true positive and false-positive 132 
variant sites, applying SNP quality metrics including allelic balance (the proportional representation of 133 
each allele in likely heterozygotes), base quality distribution for sites supporting the reference and alternate 134 
alleles, and the distribution of supporting evidence between strands and sequencing cycle, amongst others.  135 
We used as the positive training set variants identified by dbSNP or 1000 Genomes and we used variants 136 
that failed multiple filters as the negative training set.  We found this method to be effective at removing 137 
sequencing artifacts while preserving good-quality data, as indicated by the transition-transversion (ti-tv) 138 
ratio for previously known and newly identified variant sites, the proportion of high frequency variants 139 
overlapping with dbSNP, and the ratio of synonymous to non-synonymous variants, as well as attempts at 140 
validation of a subset of sites. A total of 1,908,614 SNVs passed the SVM filter. Among these, genotypes 141 
with a corresponding read depth less than 10 were set to missing.  142 
ERF 143 
The exomes of 1,336 individual from the ERF population were sequenced at the Center for Biomics of the 144 
Cell Biology department of the Erasmus MC, The Netherlands. The individuals were selected random with 145 
the regards to ADHD scores. The sequencing was performed using the Agilent version V4 capture kit on an 146 
Illumina Hiseq2000 sequencer using the TruSeq Version 3 protocol. The sequence reads were aligned to 147 
the human genome build 19 (hg19) using BWA and the NARWHAL pipeline.11,12 The aligned reads were 148 
processed further using the IndelRealigner, MarkDuplicates and TableRecalibration tools from the Genome 149 
Analysis Toolkit (GATK) and Picard (http://picard.sourceforge.net). Genetic variants were called 150 
using the Unified Genotyper tool of the GATK. About 1.4 million Single Nucleotide Variants (SNVs) were 151 
called. After removing the low quality variants (QUAL < 150), variants with a call rate of < 95% and 152 
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variants that were out of Hardy Weinberg Equilibrium (HWE; p-value < 10-6) and monomorphic variants, 153 
and removing individuals with a low call rate (< 90%) we retrieved 540,633 SNVs and 1,301 individuals. 154 
 155 
3. Whole Genome Genotyping 156 
All genome-wide genotyping has been previously reported,13 except for MrOs and SOF. Genotyping of 157 
MrOS and SOF was performed using the Illumina HumanOmni1_Quad_v1-0 B array at the Broad Institute, 158 
Cambridge, MA. Genotypes were called using the Illumina’s BeadStudio calling algorithm. The sample 159 
quality control exclusion criteria were sample call rate < 97%, excessive autosomal heterozygosity, first 160 
and second degree relatives, genotypic sex mismatch using X and Y chromosome probe intensities and 161 
gross chromosome abnormalities. 162 
Imputation of Whole Genome Genotyped Cohorts 163 
All samples were imputed using the same reference panel and pipeline. Before imputation, the phased 164 
UK10K haplotypes (3,781 samples) were merged with 1000 Genome haplotypes (1,092 samples) using 165 
IMPUTE214. We excluded singletons in both reference panels before merging. To account for the fact that 166 
each panel might contain sites that are not present in the other panel, we imputed the missing variants from 167 
each study into the other study and then combined the two reference panels as the union set of sites.15 A 168 
total of 41,992,162 variants were finally presented in the combined 9,746 haplotypes. 169 
 170 
The GWAS data were pre-phased first without a reference panel, using best-guess haplotypes.16 Then 171 
variants from the combined UK10K/1000Genomes reference panel were imputed into the best-guess 172 
haplotypes of genome wide genotyped cohorts. IMPUTE2 reports an information (info) metric as a 173 
measurement of post-imputation quality. The info metric typically takes values between 0 and 1. A value 174 
near 1 indicates a SNV has been imputed with high certainty, whereas a value of 0 means that there is 175 
complete uncertainty about the genotypes. The info metric is used to filter poorly imputed SNVs. We 176 
applied a cutoff of an info score of 0.4 to all included SNVs in the association analysis. Supplementary 177 
Table 21 denotes cohort-level imputation statistics. Separating the phasing and imputation steps in this way 178 
is beneficial because most of the computational burden of imputation comes from accounting for the 179 
unknown phase of the GWAS samples. 180 
4. Association Testing 181 
Single Variant Methods 182 
Single variant association testing was undertaken using an additive model separately for each BMD site. 183 
BMD was defined a forearm (distal 1/3 of radius), lumbar spine (L1-4) and femoral neck, as measured by 184 
DXA. Since different DXA machines have known systematic differences in BMD measurements, BMD 185 
was standardized within each cohort to have a mean of zero and a standard deviation of one. This also 186 
assists in interpretation of data since the effect size of each allele can therefore be measured in standard 187 
deviations. BMD was adjusted for age, age-squared, sex and weight. In sex-specific analyses, the sex term 188 
was removed. 189 
 190 
The type of software employed for single variant testing for each cohort is shown in Supplementary Table 191 
2. Cohort-specific genomic inflation factors (lambdas) are also shown in Supplementary Table 2 (the 192 
mean lambda was 1.044). 193 
 194 
Single variant tests were undertaken for variants with a MAF ≥0.5%, using an additive effect of the minor 195 
allele at each variant in each cohort. For single-variant tests, statistical significance was declared after 196 
taking into account all of the independent tests among variants with MAF ≥0.05%, as we have described 197 
recently.17 Briefly, to estimate the number of independent SNVs in the UK10K reference panel, we 198 
obtained sequence data from chromosome 3 on 2,577,674 genetic variants in 2,432 individuals from the 199 
UK10K program. This comprised of 798,175 SNVs with MAF ≥0.005 and the estimated number of SNVs 200 
at this threshold, genome-wide was 12,451,530. We resolved these SNVs to 4,268,111 independent tests by 201 
calculating the predicted effective number of independent tests and corrected α  = 0.05 by 4,268,111 to 202 
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yield a Bonferroni corrected genome-wide significant threshold of 1.2x 10-8 for single-variant tests at MAF 203 
≥0.5%.   204 
Single Variant Meta-analysis 205 
Meta-analysis of cohort-level SNV association statistics was undertaken using fixed-effects meta-analysis 206 
in GWAMA.18 Single variant Forest and Locuszoom plots are shown in Extended Data Fig. 2 and 10. QQ 207 
and Manhattan plots for single variant associations are shown in Extended Data Figure 1b and 1c, 208 
respectively. QQ and Manhattan plots for variants present in both exome-based and genome-based cohorts 209 
are presented in Extended Data Figure 11a and b, respectively.  Sex-stratified results for novel genome-210 
wide significant variants is provided in Supplementary Table 22. 211 
Rare Variant Analysis and Meta-analysis 212 
To test whether variants with low MAF influenced BMD we undertook a region-based collapsing method, 213 
the sequence kernel association test (SKAT), to combine information across low-frequency (MAF ≤5%) 214 
and rare (MAF ≤1%) or rare variants alone. Meta-analysis was conducted using skatMeta,19 where each 215 
cohort provided the necessary intermediate files (skatCohort objects and snpInfo files).  Analysis with 216 
skatMeta requires providing beforehand the genotypes as input to the skatCohort function.  For exome-seq 217 
data, the analysis can accommodate genotype data from an entire chromosome; however, for whole 218 
genome sequence or imputed data the analysis was not possible due to memory constraints.  As a result, 219 
genotype data was divided into gene regions, defined as the maximal extent of all isoforms of a gene, with 220 
an additional 5kb on either end.  This approach provided the flexibility to meta-analyze various subgroups 221 
of SNVs across an entire gene, such as coding variants or variants under varying evolutionary constraint. 222 
 223 
Each cohort performed the following:  224 
1. Converted genotype data to binary IMPUTE2 format using QCTOOL. 225 
2. Using custom scripts, prepared input files for analysis with skatCohort or skatFamCohort (for 226 
family-based cohorts): 227 
a. Fetch all SNVs per gene region, where a region is defined as the maximal extent of all gene 228 
isoforms plus a predefined flanking region (i.e. 5kb).  Due to computational constraints, gene 229 
regions greater than 150kb, are broken into multiple non-overlapping smaller regions of at most 230 
100kb and at least 50kb. 231 
b. For each gene region, prepare files to support analysis with skatCohort and downstream meta-232 
analysis (SNPInfo files, and SNP statistics). 233 
3. Using custom scripts, execute skatCohort or skatFamCohort per gene-region. 234 
 235 
Cohort-level skatCohort objects were meta-analyzed using skatMeta by use of a custom R script. Within 236 
each gene region, windows of 30 SNVs (overlapping by 10 SNVs) were analyzed using skatMeta with 237 
default parameters, except for the use of the skatOMeta method and the “liu” p-value method. QQ and 238 
Manhattan plots of all skatMeta results are shown in Extended Data Fig. 7a and 7b, respectively. These 239 
results demonstrate that there were few signals that departed from the line of expectation under the null. All 240 
significant findings from skatMeta were driven by single variants whose significance was also seen from 241 
single variant testing. For example, Extended Data Fig. 8a and 8c shows that the skatMeta genome-wide 242 
significant signals at CPED1 were driven by single SNVs, which were present in several cohorts. These 243 
SNVs also achieved genome-wide significance in single variant testing. We also identified a region in 244 
DOCK8 and HEXB that achieved genome-wide significance, but arose in only one cohort and we feel 245 
requires further replication (Supplementary Table 17 & Extended Data Fig. 8b). 246 
Genome-wide suggestive and significant loci from region-based association tests 247 
Supplementary Table 17 lists all genome-wide significant (P < 1.2 × 10-8) and suggestive loci (P < 1.2 × 248 
10-6) for region-based association tests. 249 
Conditional Analyses for Single Variant Associations 250 
Conditional analysis was conducted using GCTAV.0.93.9.20 This method uses an approximate conditional 251 
analysis approach from summary-level statistics from the meta-analysis and LD corrections between SNVs 252 
estimated from a reference sample. We used UK10K individuals as the reference sample to calculate the 253 
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LD information of SNVs. The associated regions flanking within 400kb of the top SNVs were extracted 254 
and the conditional analyses were conducted within these regions. A stepwise model selection procedure 255 
was performed to select independently associated SNVs with a threshold of P ≤ 5 × 10-6. Then we 256 
conditioned on these independently associated SNVs to seek secondary signals. Qualtile-quantile plots for 257 
these results are presented in Extended Data Figure 1.  Conditional analyses of individuals variants 258 
presented in Supplementary Table 6 was conducted using GCTA v 0.93.9 using default parameters. 259 
Relationship between MAF and Effect Size 260 
For each BMD phenotype, genome-wide significant SNVs (P ≤ 1.2 x 10-8) were collected and pruned for 261 
linkage disequilibrium by first placing variants into 4 discrete MAF bins: [0.005 - 0.01], [0.01 - 0.05], [0.05 262 
- 0.1], and [0.1 - 0.5]. For each MAF bin, we used the SNP Annotation and Proxy Search (SNAP)21 to 263 
calculate the pair-wise correlation (r2). We retained independent SNVs with the largest effect size by 264 
removing all the other SNVs in LD (r2 > 0.2).  265 
 266 
Power for single point tests was calculated using standard approaches.  Let  be the sample size,  be the 267 
minor allele frequency,   represent the standardized effect of a SNV on a continuous phenotype 268 
(standardized so that   is the effect per standard deviation of the phenotype), and let   represent the 269 
square of the correlation between a true genotype and a genotype measured with error.  The non-centrality 270 
parameter of the chi-squared distribution for a single SNV has been shown to be  = 2
 − 1
1 −271 
 .22   We calculated power from a non-central chi-squared distribution for the genome-wide 272 
significance threshold of 1.2x10-8 and  = 1.17 This was computed for each BMD phenotype and across 4 273 
MAF bins (0.005-0.01, 0.01-0.05, 0.05-0.1, and 0.1-0.5). 274 
Fracture Meta-analysis 275 
Fracture was defined as a bone fracture resulting from trauma of any type since even high trauma fractures 276 
are strongly associated with risk of osteoporotic fractures.  Fractures included were those occurring at any 277 
site, except fingers, toes and skull, after age 18. Both incident and prevalent fractures were included. 278 
Fractures were verified by either radiographic, casting or clinical reporting. 279 
 280 
All 1,482 genome-wide significant SNVs associated with femoral neck, lumbar spine and forearm BMD 281 
were tested for their association with risk of fracture in a sample size of 10,459 cases and 27,581 controls 282 
(38,040 total), of which 76.2% of the samples overlap the BMD discovery samples (Supplementary Table 283 
23). 284 
 285 
To obtain association statistics, in each participating study, a logistic regression model (GEE model for 286 
family-based studies) adjusted for age, age2, sex, height, weight, estrogen/menopause status (women only), 287 
ancestral genetic background (PCs) and cohort-specific covariates (such as clinical centers) was applied. 288 
The summary effect estimates for fracture risk were computed using fixed-effects inverse variance meta-289 
analysis unless heterogeneity was detected (as defined by I2 >50%), where random effects models were 290 
also used. To correct for multiple testing, we estimated the effective number of independent SNVs by 291 
principal component analyses in the UK10K sequencing dataset and found that 74 principle components 292 
explain 97% of the variance in the number of SNVs tested. We then used a Bonferroni correction to 293 
estimate the type 1 error. The multiple testing-corrected significant p-value threshold is P < 0.000676 = 294 
(0.05/74). 295 
 296 
No novel regions achieved genome-wide significance. Accounting for multiple testing for all BMD 297 
genome-wide significant SNVs rs4727923 remained nominally significant (P = 6.73x10-4; Supplementary 298 
Table 4) which marks the WNT16 locus, variants at which we have previously described as genome-wide 299 
significant for fracture.23 rs61960954 near the TNFSF11 locus, was also significant (P = 3.3 x 10-4 300 
Supplementary Table 4). 301 
Rare Variant Meta-Analysis 302 
Supplementary Table 17 demonstrates that two regions (DOCK8.1.2761-2790 and DOCK8.1.2421-2450) 303 
spanning DOCK8 on chromosome 9 were genome-wide significant in their association with femoral neck 304 
BMD (P = 1.9x10-9 and 2.8x10-9).  This arose from the analysis of all SNVs with MAF ≤1%. These regions 305 
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have low cumulative MAF (summed across the region) of 0.0055 and 0.006, respectively. To assess 306 
whether these regions-based signals were driven by multiple rare variants, or just one single variant, we 307 
undertook drop-one analysis, which recomputed the test statistic after sequentially removing one SNV from 308 
the collapsed region (Extended Data Fig. 8b). These analyses showed that signal at region 309 
DOCK8.1.2421-2450 was driven by two variants, while DOCK8.1.2761-2790 was driven by one variant. 310 
Neither of these regions contained single SNVs that achieved genome-wide significance on their own. 311 
 312 
Next, we tested which cohorts provided this association signal, by sequentially removing one cohort at a 313 
time from the test statistic and found that both regions were driven only by signal from the Framingham 314 
cohort. While promising, we feel these signals need further follow-up and replication in other cohorts. 315 
 316 
Lastly, we tested whether DOCK8 was expressed in mouse calvarial osteoblasts and found that its 317 
expression increased importantly over development (Extended Data Fig. 4a). 318 
5. Replication Genotyping and Combined Meta-analysis 319 
For lumbar spine and femoral neck BMD sites, 17 SNPs were selected to genotype in additional 13 320 
GENOMOS cohorts for replication analysis, the selection criteria of SNPs were listed in Supplementary 321 
Table 24. Human samples from the 13 GENOMOS cohorts were genotyped on LGC Genomics by KASP 322 
genotyping. KASP genotyping assays are based on competitive allele-specific PCR and enable bi-allelic 323 
scoring of single nucleotide polymorphisms (SNPs) and insertions and deletions (Indels) at specific loci. ). 324 
Replication cohorts were selected only if they contained greater than 1,000 individuals prior to genotyping 325 
quality control, given then frequency of the variants in the replication panel. Assays are deemed to be 326 
working successfully if clusters are distinct and call rates are consistently high. The data is automatically 327 
quality control checked on a per SNP basis. No Template Controls (NTCs) are included on each plate to 328 
enable the detection of contamination or non-specific amplification. Two SNPs (rs13046645 and 329 
chr3:50906922) were found to be monomorphic in initial test GENOMOS cohorts, thus, only 15 SNPs 330 
were genotyped. For replication of rs148771817 for forearm BMD, genotyping was undertaken in a single 331 
cohort, since this phenotype is rarely collected in population-based cohorts. Genotyping for this SNP was 332 
similarly done at LGC Genomics using KASP genotyping in the AOGC cohort, where the age distribution 333 
was matched to the discovery cohorts (age cutoff of <80 years was used). Genotyping quality metrics for 334 
all variants are provided in Supplementary Table 25. 335 
 336 
The genotyping data of the 16 SNPs were formatted into PLINK, the BMD phenotype were adjusted by sex, 337 
age, age2, weight and standardized to have a mean of zero and a standard deviation of one within each 338 
cohort. The association analysis were performed by PLINK in each cohort, then combined analysis of the 9 339 
discovery GEFOS cohorts and 13 GENOMOS cohorts of the 16 SNPs were conducted with GWAMA. 340 
Cohort-level association results are provided in Supplementary Table 26. Meta-analysis results from 341 
replication cohorts as well as combined discovery/replication cohorts are provided in Supplementary 342 
Table 27.   343 
 344 
Non-reference discordant rate (NRD) presented in main text and Supplementary Table 5 was computed as 345 
the proportion of non-reference genotypes found to be discordant between compared individuals as 346 
compared total measured non-reference genotypes for that variant. For imputed variants, genotype 347 
probabilities where converted to hard-calls using a genotype probability of 0.9. 348 
6. Functional Genomics 349 
Functional Class Enrichment 350 
To ascertain if functional classification using GERP++ scores8 enriches for more significant GWAS 351 
associations, we computed, for variants that fall below or above a series of GERP++ thresholds the 352 
proportion that surpass FDR q-value of 0.05.  Prior to FDR analysis, variants from meta-analysis (UK10K 353 
+ 1KG reference panel SNVs only) were annotated with GERP++ scores and distance to the nearest gene.  354 
Variants were then pruned for LD with PLINK using an r2 of < 0.2, window size of 100kb and step of 20 355 
kb.  For each SNV in this LD independent set, we selected the single SNV in LD with the lowest p-value, 356 
thus yielding a final dataset of LD independent SNVs with lowest p-values.  For each GERP++ threshold 357 
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considered (from 0 to 4, with step of 0.2), we partitioned SNVs into those above (cases) and below 358 
(controls) the threshold.  To adjust for bias (such as a correlation of GERP++ score to gene distance or 359 
MAF) we matched cases to controls using the R package MatchIt (coarsened exact matching algorithm). 360 
Subsequent to matching, FDR analysis was conducted on each set of case and control variants, and 361 
proportion of variants surpassing FDR q-value of 0.05 was obtained. 362 
 363 
For synonymous and deleterious variants, the above strategy was applied, except only coding variants were 364 
partitioned based on whether or not they were synonymous or deleterious.  Variant annotations were 365 
computed using a local version of Variant Effect Predictor.7 Deleterious variants were classified as having 366 
the following sequence ontology terms (frameshift_variant, inframe_deletion, inframe_insertion, 367 
initiator_codon_variant, missense_variant, splice_acceptor_variant, splice_donor_variant, stop_gained, and 368 
stop_lost).  369 
Chromatin Accessibility: DNase I Hypersensitivity Site Correlations  370 
For distal/promoter DHS correlation analyses, we utilized DHS data from ENCODE for 305 cell lines 371 
(Supplementary Table 28).  The distal DHS regions were defined as a peak region from ENCODE DHS 372 
data that overlapped the GWAS SNP. For rs148771817 (WNT16 locus), the peak region was obtained from 373 
the “Digital DNase I Hypersensitivity Clusters in 125 cell types from ENCODE” track from the UCSC 374 
Genome Browser. For rs188303909, (EN1 locus), the peak region was obtained from the “Osteoblasts 375 
DNase I HS Peaks from ENCODE/Duke” track from the UCSC Genome Browser. Promoter regions were 376 
defined as 500 nucleotide flanking the TSS of genes within 500 Kb of the GWAS SNP being considered.  377 
Within each of these promoter or distal DHS regions, we obtained the DHS measurements for all 378 
overlapping 100nt bins across the 305 cell lines.  Correlation analyses between the distal and promoter 379 
DHS 100 nucleotide bins was conducted using Pearson correlation in the R statistical software package.  380 
For each distal nucleotide bin, the maximal R2 to across all bins per gene promoter region was reported. 381 
Results for EN1 and WNT16 loci are shown in Supplementary Tables 7 & 11, and Extended Data Fig. 3. 382 
ENCODE Analysis of EN1 variant rs188303909 383 
A genome-wide significant SNV 7kb upstream of EN1 (rs188303909[T], MAF= 2.0%, effect size from 384 
replication cohorts = +0.14 SD, Pmeta= 1.3 x 10-9) overlaps a DNase I hypersensitive site (DHS) in 385 
osteoblasts bound by CTCF (Extended Data Fig. 3a) as well as histone marks. We found evidence of 386 
moderate correlation in chromatin accessibility between rs188303909 and the promoter of EN1 across 305 387 
cell types24 (maximum r2 = 0.59, P= 1.5 x 10-29, Supplementary Table 7, Extended Data Fig. 3a), 388 
suggesting that the DHS overlapping rs188303909 may regulate expression of EN1. Hi-C data in human 389 
embryonic stem cells further supports an interaction between the rs188303909 DHS and the EN1 promoter, 390 
as both sites lie within the same topologically associated domain (TAD).25 Similarly, chromatin interaction 391 
analysis by paired-end tag sequencing (ChIA-PET) data in MCF-726 cells also supports an interaction 392 
between rs188303909 and EN1 (Figure 1). 393 
ENCODE Analysis of CPED1/WNT16 variant rs148771817 394 
A genome-wide significant within an intron of CPED1 (rs148771817 [T], MAF= 0.9%, replication effect 395 
size= +0.41 SD, Pmeta= 1.1 x 10-11) overlaps a DNase I hypersensitive site (DHS) in 14 cell types 396 
(Extended Data Fig. 3b). We found evidence of moderate correlation in chromatin accessibility between 397 
rs148771817 and the promoter of WNT16 across 305 cell types24 (Supplementary Table 11, Extended 398 
Data Fig. 3b), suggesting that the DHS overlapping rs148771817 may regulate expression of WNT16. Hi-C 399 
data in human embryonic stem cells supports an interaction between the rs148771817 DHS and the WNT16 400 
promoter, as both sites lie within the same topologically associated domain (TAD).25 However, interaction 401 
frequency to nearby regions is also elevated (Supplementary Table 11).  402 
7. Functional Experiments 403 
Murine Osteoblast Gene Expression Profiling 404 
Pre-osteoblast-like cells were obtained from neonatal calvaria collected from C57BL/6J mice expressing 405 
cyan florescent protein (CFP) under the control of the Col3.6 promoter (pOBCol3.6CFP), using standard 406 
techniques.27 pOBCol3.6CFP mice used with permission for this study.  These mice were made in an 407 
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identical fashion to the previously described pOBCol3.6GFPtpz transgenic mice.27 The cells were placed 408 
into culture for 4 days in growth media (DMEM containing 10% fetal bovine serum (FBS) and 1X 409 
penicillin/streptomycin), removed from culture by trypsin digestions and subjected FACS sorting based on 410 
the presence/absence of CFP expression to allow for enrichment of osteoblast lineage cells.  Cells 411 
expressing CFP were returned to culture, plated at a density of 1x104 cells per cm2, subjected to an 412 
osteoblast differentiation cocktail (αMEM containing 50 µg/ml Ascorbic Acid, 4 mM β-glycerol phosphate, 413 
10% FBS and 1X penicillin/streptomycin) and RNA was collected at 2, 4, 6, 8, 10, 12, 14, 16 and 18 days 414 
post differentiation. To examine gene expression across osteoblastogenesis, mRNA profiles for each time 415 
point were generated by Next Generation High throughput RNA sequencing (RNAseq), using an Illumina 416 
HiSeq 2000.   Three technical replicates per sample were sequenced. The alignments for abundance 417 
estimation of transcripts was conducted using Bowtie version 0.12.928  using the NCBIm37 transcriptome 418 
as the reference for alignments. Among all the possible alignments that had fewer than or equal to three 419 
mismatches against reference transcriptome, we only accepted those with the minimum number of 420 
mismatches for each of 100bp read (using both ‘--all’ and ‘--best’ options).  Expression level per gene was 421 
calculated using RSEM version 1.2.0 using the following parameters: --fragment-length-mean 280 and --422 
fragment-length-sd 50 and expression level for each sample was normalized relative to the per sample 423 
upper quartile.29,30 This data has been submitted to the gene expression omnibus (Accession Number: 424 
GSE54461). Results from these experiments for Dock8 are shown in Extended Data Fig. 4a. 425 
Temporal Expression of En1 in Mouse Osteoblasts and Osteoclasts 426 
Pre-osteoblast-like cells were obtained from neonatal calvaria collected from C57BL/6J mice using 427 
standard techniques.  The cells were placed into culture for 4 days in growth media (DMEM containing 428 
10% fetal bovine serum (FBS) and 1X penicillin/streptomycin) at a density of 2x104 cells per cm2.  The 429 
pre-osteoblast cells were subjected to an osteoblast differentiation cocktail (αMEM containing 50 µg/ml 430 
Ascorbic Acid, 4 mM β-glycerol phosphate, 10% FBS and 1X penicillin/streptomycin) and RNA was 431 
collected at 2 and 18 days post differentiation.  These cells were independent from the cells used for the 432 
RNA-seq experiments and were not subjected to FACS. Bone marrow derived osteoclast precursor cells 433 
were isolated from the hind long bones (femur and tibia) of six week old C57BL/6J female mice. In short, 434 
bone marrow was flushed from the long bones and marrow stromal cells were plated at a density of 1x106 435 
cells per cm2 in αMEM containing 10% FBS, macrophage colony-stimulating factor (25 ηg/ml) and 436 
RANKL (100 ηg/ml).  Media was changed at day three post plating and RNA was collected three days 437 
after that (day six post plating). Each lane for gene expression represents data from one mouse for the 438 
osteoclasts cultures and from one well of cells for the osteoblast cultures.   For both the osteoclasts and the 439 
osteoblast samples, total RNA was isolated using TriZOL (Life Technologies, USA), as described by the 440 
manufacturer, and RNA was treated with DNase to remove any contaminating DNA. For each sample, 500 441 
ηg of RNA were then converted to cDNA using standard protocols, with random decamers used as primers 442 
for the reaction. Expression of En1, Bglap (osteocalcin) and Tnfrsf11a (RANK) was assessed by PCR.  For 443 
each PCR reaction, 2 μl of cDNA was added to 48 µl of master mix containing 5 μl of 10X PCR Buffer 444 
(Clontech), 0.4mM dNTP’s, 2 µM of each of a forward and a reverse primer, 1 µl of Taq (Clontech) with a 445 
balance of ddH2O. The PCR was completed using the following cycling conditions: 1 minute (min) hold at 446 
94ºC and 30 cycles of 94ºC for 30 sec and 68ºC for 3 min, followed by a hold at 68ºC for 3 min.  The 447 
following primers were used:  En1 forward: TCA AGA CTG ACT CAC AGC AAC CC, En1 reverse: TTG 448 
TCC TGA ACC GTG GTG GTA GAG, Bglap forward: CCA TCT TTC TGC TCA CTC TGC TG, Bglap 449 
reverse: CTT CAA GCC ATA CTG GTC TGA TAG C, Tnfrsf11a forward: CCA TCA TCT TCG GCG TTT 450 
ACT ACA G and Tnfrsf11a reverse: GGA TTA GGA GCA GTG AAC CAG TCG.  PCR products were 451 
visualized by separating them on a standard 2% agarose gel stained with Ethidium Bromide. 452 
Quantitative Expression of En1 453 
iCycler iQ thermal cycler 454 
For osteoblast marker gene expression, total mRNAs were purified from osteoblast cultures. Real time PCR 455 
was performed in triplicate using the iCycler iQ thermal cycler and detection system (Applied Biosystems, 456 
Carlsbad, CA) following the manufacturer’s protocols. Expression of the tested gene was normalized 457 
relative to levels of GAPDH. Primers used are: mALP forward: CAC AAT ATC AAG GAT ATC GAC 458 
GTG A,  mALP reverse: ACA TCA GTT CTG TTC TTC GGG TAC A, mOSX forward: ATG GCG TCC 459 
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TCT CTG CTT GA mOSX reverse: GAA GGG TGG GTA GTC ATT TG, mBglap forward: GGG CAA 460 
TAA GGT AGT GAA CAG mBglap reverse: GCA GCA CAG GTC CTA AAT AGT, mRunx2 forward: 461 
TAC AAA CCA TAC CCA GTC CCT GTT T, mRunx2 reverse: AGT GCT CTA ACC ACA GTC CAT 462 
GCA, mCol1a1: forward ACT GTC CCA ACC CCC AAA G, Ccol1a1 reverse: ACG TAT TCT TCC 463 
GGG CAG AA. For results see Extended Data Fig. 4d. Expression within sdEn1 is likely due to detection 464 
of the non-functional En1Cre allele. 465 
 466 
StepOnePlus Real Time PCR system 467 
Total RNA from whole vertebral bone extract was prepared using TRIZOLreagent (Sigma) followed by 468 
RNeasy Mini Kit (Qiagen). The RNA was reverse transcribed into cDNA using cDNAkit (Appled 469 
Biosystems) and real-time PCR analysis was performed using custom designed real-time PCR assays and 470 
the StepOnePlus Real Time PCR system (Applied Biosystems). Primers used are: forward ACT CAT GGG 471 
TTC GGC TAA CG, reverse GAC GGT CCG AAT AGC GTG T, and probe CGG TGG TCA AGA CTG 472 
ACT CA. 18S ribosomal RNA (4310893E Applied Biosystems) was included as an internal standard. For 473 
results see Extended Data Fig. 4e. Expression within sdEn1 is likely due to detection of the non-functional 474 
En1Cre allele. 475 
Murine bone histology 476 
Mouse bone tissue preparation: Two-month old En1lacZ/+ mice31 were euthanized by CO2 suffocation and 477 
the vertebrae from T13 to S1 were collected as a whole block on ice-cold phosphate-buffered saline (PBS). 478 
Soft tissue was gently removed with blunt scissors and a size-11 surgical blade, until the intervertebral 479 
discs were visible. The vertebral blocks were then fixed by immersion in 0.25% glutaraldehyde in PBS for 480 
90 minutes at room temperature (RT). After several washes with PBS, the vertebrae were decalcified for 4 481 
days with EDTA 0.5M pH 7.4 at 4°C (2 changes per day), followed by further washes with PBS. The tissue 482 
was then cryoprotected by incubation with a solution of 30% sucrose in PBS overnight at 4°C, and then 483 
embedded in OCT compound (Tissue-Tek) using dry-ice-cold isopentane (Sigma). 484 
  485 
Histochemical methods: 10-micron sections were collected with a Leica Cryostat on SuperFrost slides 486 
(Fisher) and allowed to dry overnight. Sections were stored at –80°C until use. For enzymatic detection of 487 
β-galactosidase activity, slides were allowed to reach room temperature (RT) in a closed box, and OCT was 488 
washed away for 15 minutes with warm PBS (37°C), followed with several extra PBS washes. The sections 489 
were post-fixed 5 minutes with 4% paraformaldehyde (PFA, Electron Microscopy Sciences) in PBS at RT. 490 
After PBS washes, the sections were incubated 2x5 minutes with X-gal buffer (2mM MgCl2, 0.02% NP40 491 
and 0.05% deoxycholate in PBS 0.1M pH 7.4) and then overnight at 37°C in X-gal reaction buffer (20 492 
mg/ml X-gal, 5mM K4Fe(CN)6 and 5mM K3Fe(CN)6 in X-gal wash buffer). After PBS rinses, the sections 493 
were postfixed 10 minutes in 4% PFA and PBS-rinsed again. At this point, if only X-gal staining was 494 
required, the sections were then counterstained with Nuclear Fast Red 0.005% for 15 minutes, serially 495 
dehydrated, incubated 3x1 min with xylene, and cover-slipped using DPX mountant (Fisher). If Alkaline 496 
Phosphatase (AP) activity was also required, the sections were incubated 2x5 minutes with AP buffer 497 
(100mM NaCl, 50mM MgCl2, 0.1% Tween-20 in Tris-HCl 0.1M pH 8.2) and AP activity was revealed by 498 
incubation with Fast Red (2 h at 37°C) following manufacturer instructions (Roche). After PBS rinses, a 499 
gelatin/Tris mounting medium was used to coverslip the slides. 500 
 501 
Imaging: Z-stacked DIC images were captured of the LacZ and AP double-stained lumbar vertebrae from 502 
2-month old En1lacZ/+ reporter mice at 400x using a Nikon Eclipse Ni-E upright microscope and NISAr 503 
software. 504 
Mouse Micro-CT 505 
Mice: The En1Cre/+ and En1flox/+ mouse strains32,33 were maintained in a mixed background and genotyped 506 
as described. Male En1Cre/+ mice were crossed with En1flox/flox females to generate experimental and control 507 
animals. 508 
 509 
Tissue collection, preparation and imaging: Lumbar vertebrae from levels L4 to L6 were collected from 4-510 
month old En1Cre/flox (self-deleted conditional En1 mutants, sdEn1; n=5), and compared to En1+/flox 511 
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littermates (control; n=6). All vertebrae were cleaned of soft tissue, fixed in 4% PFA (paraformaldehyde) 512 
overnight, washed three time in 1XPBS for 30 mins each, and stored in 70% ethanol at 4°C until scanning. 513 
Before scanning, the bones were allowed to reach room temperature. L5 vertebral body starting 100μm 514 
from the growth plates were used for trabecular bone micro-computed tomography (microCT, μCT) 515 
analysis on Scanco μCT 35 (Scanco Medical, Brüttisellen, Switzerland) system. 6μm voxel size, 55KVp, 516 
0.36 degrees rotation step (180 degrees angular range) and a 400ms exposure per view were used for the 517 
scans, which were performed in 70% ethanol. The Scanco μCT software (HP, DECwindows Motif 1.6) was 518 
used for 3D reconstruction and viewing of images. After 3D reconstruction, volumes were segmented using 519 
a global threshold of .4g/c.  Directly measured bone volume fraction (BV/TV), thickness (Tb.Th), number 520 
(Tb.N) and separation (Tb.Sp), TMD and surface to volume ratio (BS/BV) were calculated for the 521 
trabecular bone.  522 
 523 
Extended Data Figure 6e presents the microCT parameters for data in Supplementary Table 29.  524 
Significance between control and sdEn1 mutants was computed using an unpaired t-test. The thickness map 525 
of the 3D image reconstructed microCT image of the LV5 shows the spatial distribution of the mineral 526 
density and is presented in Extended Data Figure 6a, with morphological characteristics presented in 527 
Extended Data Figure 6b.  Extended Data Figure 6c and 6d also presents mictoCT and morphological 528 
characteristics for femur trabecula and cortical bone.    529 
Dynamic and Cellular Histomorphometry 530 
Mice for skeletal testing and laboratory blinding:  The same animals were used for histomorphometry as 531 
MicroCT. Histomorphometry labs (Rower and Ackert) and MicroCT labs (Dahia and Joyner) were blinded 532 
to the results of each other’s analyses.  533 
 534 
Sample collection: Prior to sacrifice, mice received intraperitoneal injections of 10 mg/kg calcein (Sigma 535 
C-0875) and 30 mg/kg alizarin complexone (Sigma A-3882) at 7 and 2 days, respectively, prior to sacrifice.  536 
The dynamic mineralization activity measurements, which are dependent on being able to detect these dyes 537 
in the bone, suffered from a loss of 2 animals in each group due to inadequate uptake of one of the two 538 
mineralization dyes. The right hind limb was dissected from the hip, and skin and non-adherent muscle and 539 
connective tissues were removed from the bone, without scraping periosteal surfaces.  The marrow space 540 
was exposed by excising the proximal femur and distal tibial bone leaving with knee joint intact.  In 541 
addition, the vertebra bodies from L1 through L3 were dissected free of adherent muscle.  The samples 542 
were placed in 10% formalin at 4oC and shipped to Rowe laboratory.  Upon receipt, the samples completed 543 
a 3-day exposure to formalin and subsequently were place in 30% sucrose at -80º C until all the samples 544 
had been collected.   545 
 546 
Tissue sectioning: Samples were entered into a modification of the fluorescence-based computer-automated 547 
dynamic and cellular bone histomorphometry as described by Hong et al.34  The workflow and staining 548 
protocols are detailed at the bonebase.org, and is briefly outlined here.  Three to four distal femur or 549 
vertebral bodies are embedded in the sample mold with the aid spacing device and held in place with 550 
layering of the cyro-embedding medium (OCT, ThermoScientific).  The ice blocks are positioned on 551 
cryostat (Leica CM3050 S) and oriented to cut the multiple bones in the same plane of section.  Three 5 µm 552 
sections are collected at 100 µm levels using an adhesive cryotape (Cryofilm type IIC(10), Section Lab, 553 
Japan.) to capture and maintain the morphology of the section.  The tape is bonded to a glass slide 554 
(Cryojane, Leica Cat# 39475208) using UV fixation with the sample side exposed.  Each slide contains two 555 
tapes with all the sections from the Control or sdEn1 samples as well as spots of fluorescent beads (5-556 
10µm) for subsequent image registration.   Three slides per the Control and sdEn1 samples containing the 3 557 
levels of section are processed in a single batch for the staining and imaging steps. 558 
 559 
Section staining: In the first step, the samples are incubated for 5 min in a calcein blue solution to identify 560 
the accumulated mineral with a fluorescent signal.  The slide is cover-slipped with 30% glycerol and 561 
imaged for accumulated mineral and the calcein and alizarin complexone (AC) mineralization lines.  The 562 
second step removes the coverslips and place the slides in a tartrate acid (TRAP) incubation buffer, 563 
followed by 5 minutes in the reaction buffer that contains the fluorescent substrate Elf97.  The acid 564 
conditions remove all the mineralization signals used in the first step.  The slides washed in PBS and cover-565 
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slipped with 30% glycerol.  The TRAP positive cells and registration beads are captured in the second 566 
scanning step.  The third step removes coverslip and incubates the sections in the alkaline phosphatase (AP) 567 
reaction buffer and followed by 10 minutes in the reaction buffer containing fast red substrate.  The PBS 568 
washed slides are cover-slipped with 30% glycerol/water containing DAPI.  The slides are imaged for the 569 
red AP signal, DAPI positive nuclei and registration beads.  The final step removes the cover slips and 570 
stains the slides with toluidine blue to provide visual tissue morphology and identify cartilage proteoglycan 571 
of the articular cartilage and growth plate.  The slides are cover-slipped again in 50% glycerol/water and 572 
imaged from chromogenic signals.   573 
 574 
Section imaging:  The six slides, each containing 5-6 bone sections, are placed in 3 of the 4 positions of the 575 
slide holder and loaded into the slide magazine of the Axioscan Z1 microscope.  The software recognizes 576 
the bar code of the slide and identifies the individual sections on the slide to create an image file for each 577 
section.  The operator refines the region of interest (ROI) to be scanned and initiates the scanning 578 
procedure using preset exposure times and excitation/emission settings.  The light source is the Colibri.2 579 
and the image is captured with a high-resolution monochromic digital camera (Zeiss MRm Rev.3).   The 580 
DAPI, calcein blue and tetracycline sections were excited with the 385nm LED, calcein with the 470nm 581 
LED, and the AC and fast red with the 555nm LED.  The emission filters used Chroma, #49000ET (LP 400, 582 
Emission 460/50) for calcein blue and DAPI, Chroma #49003ET (LP 515, emission 535/30) for calcein, a 583 
custom Chroma filter (LP 425, emission 555/30) for tetracycline and Chroma 49005ET (LP 570, emission 584 
600/50) for AC and fast red.  The toluidine blue stain section uses a tungsten light source and Hitachi HV-585 
F202 camera.  Using a Plan-Apochromat 10x/0.45 WD objective, the entire ROI is captured at 100X using 586 
an automated image stack compression algorithm.  587 
 588 
Image Analysis:  The Axioscan generates proprietary multilevel source files that are exported as individual 589 
gray scale jpeg files for each filter setting.  The files average approximately 65 megapixels per image, 590 
which is about 10 pixels per µm2 and corresponds to the size of a DAPI positive nucleus.  A total of 9 gray 591 
scale files and 1 color file are generated.  A proprietary algorithm was utilized to threshold each fluorescent 592 
signal and map it back to the mineralized bone architecture as defined by the calcein blue stain.34   The 593 
details of the analysis and the production of measured and calculated data are detailed at bonebase.org. 594 
Osteoblastic activity is assessed by a fluorescent AP stain, which is strongly positive in active osteoblasts 595 
but still detectable by resting (lining) cell of the bone lineage.  The histology measures the proportion of 596 
trabecular bone surface (BS) that is positive for AP activity (AP/BS).  To control for technical or biological 597 
variation in staining activity, the distribution of that signal between bone labeling surfaces (AP_L_BS) and 598 
non-labeling surfaces (AP_NL_BS) is calculated.   Another measurement that is independent of the total 599 
AP activity of a tissue, distributes the proportion of AP activity that is adjacent to mineralizing surfaces 600 
(%AP_L) or non-labeling surfaces (%AP_NL).  Osteoclastic activity is based on a fluorescent TRAP stain 601 
and expressed as the proportion of trabecular bone surface that is TRAP positive (TRAP_BS).  The analysis 602 
does not account for the size of the individual spots of activity nor the number of nuclei per fluorescent spot.  603 
Only activity that resides adjacent to the trabecular surface and not within the marrow space is assessed.  604 
The distribution of the TRAP activity to sites of active mineralization (TRAP_L_BS) or osteogenesis 605 
(AP_TRAP_BS) versus inactive mineralization (TRAP_NL_BS) has proven to be a useful measurement to 606 
discriminate areas of high bone turnover versus bone resorption without an osteogenic response. 607 
Identification of cells belonging to the En1 lineage 608 
Breeding of mice and sample collection:  Twelve week old En1Cre/+;R26LSL-EYFP (En1 lineage tagged) and 609 
En1+/+;R26LSL-EYFP (control) mice were sacrificed, the vertebral 1-3 were excised, placed in chilled 10% 610 
formalin, packed in wet ice and sent to the Rowe lab for imaging. 611 
 612 
Tissue process, sectioning and imaging:  The tissues and sectioning protocol was identical to 613 
histomorphology including the multiple rounds of imaging and staining.  The EYFP signal was captured 614 
during the first imaging step using the Colibri.2  470nm LED and the Chroma 49003ET filter (LP 515, 615 
Emission 535/30).  The EYFP signal from the R26LSL-EYFP allele is very weak in skeletal tissues requiring 616 
significant signal enhancement. (Extended Data Figure 5) 617 
 13 
Human EN1 Expression Profiling 618 
Human CD14+ cells from healthy donors were incubated with 20 ng/ml of human M-CSF (peprotech) for 619 
one day to generate OCPs. Osteoclast precursors were incubated with 20 ng/ml of M-CSF and 40 ng/ml of 620 
human soluble RANKL for five additional days in α-MEM supplemented with 10 % FBS. Cytokines were 621 
replenished every 3 days. On day 6, cells were harvested. mRNA of human osteoclasts (n=5), human 622 
macrophges (n=4), 293T cells (fibroblasts, n=4), and human osteoblasts (a kind gift from Dr. Jae Hycuk 623 
Shim, Weill Conell Medical College, n=3) was measured using real-time PCR. EN1 mRNA levels were 624 
normalized relative to GAPDH mRNA. Data are shown as mean ± SEM. *** :P < 0.001 by one-way 625 
ANOVA. All statistical analyses were performed with Graphpad Prism 5.0 software one-way ANOVA for 626 
multiple comparisons (more than two conditions) with posthoc Tukey test.  p<0.05 was taken as 627 
statistically significant. Results are presented in Extended Data Fig. 4c. 628 
Mouse and Rat Homologous Regions 629 
To test possible conservation between human BMD-associated loci and quantitative trait loci (QTLs) linked 630 
to bone related traits in experimental mapping panels in rats and mice, comparative genome data were used. 631 
For each region of association to BMD in humans, genes flanking SNV markers showing the strongest 632 
evidence of association were searched for homologs in the genome assemblies of the mouse 633 
(NCBI37/mm9) and rat (RGSC3.4). For the rat QTL, the corresponding locus was tested for co-localization 634 
within boundaries of QTLs for bone related phenotypes fine mapped (circa 4Mb) from the heterogeneous 635 
stock (HS).35 For QTL in mice, the peak SNV location was converted to CentiMorgan (cM) distance, as per 636 
the Cox-Sex-Average genetic map36 using the freely available Mouse Map Conversion Tool 637 
(http://cgd.jax.org/mousemapconverter/).  All identified mouse QTLs37 mapped within a peak location 5 638 
cM either side of the human peak SNV and are listed, along with the strain pair(s) used to identify the 639 
original QTL. Results for these analyses are shown in Supplementary Table 9. 640 
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